Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO).
J Am Acad Dermatol
; 91(1): 64-71, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38431099
ABSTRACT
BACKGROUND:
Weight loss is reported with oral roflumilast, which is approved for chronic obstructive pulmonary disease (COPD). Recently, the drug has shown efficacy in psoriasis, a disease strongly linked to overweight/obesity.OBJECTIVE:
To describe the effects of oral roflumilast on body weight and cardio-metabolic parameters in patients with psoriasis.METHODS:
Posthoc analyses from the PSORRO study, where patients with moderate-to-severe plaque psoriasis were randomized 11 to oral roflumilast 500 µg once-daily or placebo for 12 weeks, followed by active, open-label treatment through week 24 in both groups. Changes in body weight, blood pressure, gastrointestinal symptoms, and laboratory tests were registered. No lifestyle or dietary interventions were applied.RESULTS:
Forty-six patients were randomized. Baseline characteristics across groups were comparable; mean weight was 103.6 kg. In patients receiving roflumilast, median weight change was -2.6% and -4% at week 12 and 24, respectively. Corresponding numbers were 0.0% and 1.3% in patients initially allocated to placebo. Reduced appetite was more frequent with active therapy. No changes in blood pressure or laboratory tests were observed.LIMITATIONS:
Posthoc analyses and low numbers.CONCLUSION:
Oral roflumilast induced weight loss and reduced appetite, which support the growing evidence of roflumilast as an attractive treatment alternative for patients with psoriasis.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Benzamides
/
Weight Loss
/
Cyclopropanes
/
Phosphodiesterase 4 Inhibitors
/
Aminopyridines
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Am Acad Dermatol
/
J. Am. Acad. Dermatol
/
Journal of the American Academy of dermatology
Year:
2024
Type:
Article